Oxonica Signs Follow-on Research and Development Agreement with BD |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Oxonica Limited
7 Begbroke Science Park
Yarnton, Kidlington , Oxford, OX5 1PF
United Kingdom
Press release date: September 27, 2007
27th September 2007
Oxonica plc
Oxonica plc ("Oxonica"), a leading international nanomaterials group, today is pleased to announce that it has signed a follow-on research and development agreement with BD (NYSE: BDX) using Oxonica's Nanoplex(TM) technology. Under the terms of the agreement, BD will fund a new research program in order to continue further evaluation of the technology's feasibility.
Under the original 2006 licensing and investment agreement, BD subscribed to fund a joint research program focused on enabling Oxonica's technology to be potentially used in rapid diagnostics. "This new agreement continues BD's exploration of our Nanoplex(TM) technology, and enhances the development prospects of future innovative products," said Kevin Matthews, CEO of Oxonica.
"We are excited about the progression of our relationship and look forward to helping BD successfully achieve their research goals, while continuing to improve our quality and manufacturing systems," added Tamara St. Claire, VP of Business Development at Oxonica, Inc.
Oxonica's Nanoplex(TM) technology is based on a series of encapsulated gold nanoparticles, each with a unique spectral signature. These "labels" have the potential to be attached to a wide range of biological markers, thus enabling the possibility of a new diagnostic paradigm.
For further information, please contact: Oxonica plc 01865 856 700 Kevin Matthews, Chief Executive
Richard Clarke, Finance Director
The Broadcast PR Business 0207 812 6624 Matthew Locke
About Oxonica plc - www.oxonica.com
Oxonica (AIM: OXN.L) is one of the leading international nanomaterials groups with products already launched into international markets and is listed in London on the AIM market. It was spun-out from Oxford University in 1999. Oxonica's mission is to focus on the development of innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. It owns a portfolio of demand driven products that offer substantial benefits to the target markets of energy, healthcare, materials and security.
The Group currently has four operating divisions: Oxonica Energy, Oxonica Healthcare, Oxonica Materials and Oxonica Security. Oxonica has already launched products into international markets. Lead products include:
o Envirox(TM) fuel borne catalyst - a nanocatalyst improving fuel economy and reducing emissions
o Optisol(TM) UV absorber - a revolutionary photostable UV protection system designed to optimise the performance of quality sunscreens and anti-premature aging products
Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection technologies which will enable a new generation of ultrasensitive multiplex diagnostic tools for the clinical diagnostic life science and security markets. In addition, Oxonica is developing other UV absorber technologies into polymer systems and coatings, based on similar technologies to that used in Optisol(TM).
|
|
|
|
|
See related product stories
|
|
|
|
|
|
|
|
|
|
| 
